Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. Februar 2018 14:00 ET | Quelle: Aviragen Therapeutics, Inc.

Aviragen Adjourns Special Meeting of Stockholders to Allow Stockholders to Consider Improved Merger Deal Terms

CAS Group Supports Improved DealCompany Currently has Sufficient Votes to Approve Merger ATLANTA, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced that...
07. Februar 2018 15:22 ET | Quelle: Aviragen Therapeutics, Inc.

Aviragen and Vaxart Amend Terms of Merger Agreement to Increase the Value for Aviragen Stockholders

ATLANTA and SOUTH SAN FRANCISCO, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) and Vaxart, Inc. today announced that the companies have agreed to amend the...
06. Februar 2018 10:25 ET | Quelle: Aviragen Therapeutics, Inc.

Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018

ATLANTA, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced that its Special Meeting of Stockholders, scheduled for and convened on February 6, 2018, has...
31. Januar 2018 18:15 ET | Quelle: Aviragen Therapeutics, Inc.

Aviragen Provides New Information Supporting Vote FOR Vaxart Merger

Reiterates Transaction Represents Best Path Forward for Aviragen and ALL Stockholders CAS Group Has Not Articulated a Clear Plan and Has Now Changed its Stance to Emphasize Teslexivir (BTA074) ...
26. Januar 2018 15:59 ET | Quelle: Aviragen Therapeutics, Inc.

Aviragen Comments on ISS Report

Vaxart Merger is the Result of an Extensive Review of Strategic Alternatives and is in the Best Interest of ALL Stockholders Aviragen Board of Directors Unanimously Recommends that Stockholders Vote...
24. Januar 2018 14:55 ET | Quelle: Aviragen Therapeutics, Inc.

Aviragen Therapeutics Issues Letter to Stockholders

Reiterates Benefits of Proposed Merger with Vaxart Urges All Aviragen Stockholders to Vote FOR the Proposed Merger on the WHITE Proxy Card Today ATLANTA, Jan. 24, 2018 (GLOBE NEWSWIRE) --...
11. Januar 2018 19:09 ET | Quelle: Aviragen Therapeutics, Inc.

Aviragen Board Of Directors Unanimously Recommends That Stockholders Vote FOR The Proposed Merger With Vaxart

Transaction Creates a Leading Vaccine Company and Maximizes Value for Aviragen Stockholders Updated Investor Presentation Filed with Securities and Exchange Commission and Posted to Aviragen Website ...
29. November 2017 07:00 ET | Quelle: Aviragen Therapeutics, Inc.

Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma

ATLANTA, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the discovery and development of direct-acting antivirals to treat infections that have...
02. November 2017 07:00 ET | Quelle: Aviragen Therapeutics, Inc.

Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results

ATLANTA, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three months ended September 30, 2017. “Earlier this week we were...
30. Oktober 2017 07:00 ET | Quelle: Aviragen Therapeutics, Inc.

Aviragen Therapeutics and Vaxart Enter into Merger Agreement

Merged Company to Focus on Development of Antiviral Vaccines and Therapeutics Based on Proprietary Delivery Technology Platform Conference Call to be Held Today at 8:30 AM ET ATLANTA and SOUTH...

Vorherige Seite